Purpose of this Study
People in this study will be placed into one of two groups by chance, like flipping a coin. One group will get two medicines called DSP107 and Atezolizumab together. The other group will get a medicine called Fruquintinib by itself. Each treatment cycle lasts 4 weeks and can continue for up to 2 years. Doctors will check health and safety during the study. After the last dose, there will be a follow-up period of up to 90 days.
Who Can Participate?
Eligibility
People can join this study if they are 18 years or older and are expected to live for more than 3 months. They must have a type of colon cancer called microsatellite stable (MSS) or proficient mismatch repair (pMMR) colorectal cancer.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
The goal of this study is to learn if people with a type of colon cancer called microsatellite stable colorectal cancer do better when treated with two medicines, DSP107 and Atezolizumab, compared to those who get Fruquintinib.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination with Atezolizumab Versus Fruquintinib in Patients with Advanced Microsatellite Stable Colorectal Cancer
Principal Investigator
Nicholas
DeVito
Protocol Number
PRO00119461
NCT ID
NCT07235293
Phase
II
Enrollment Status
Pending Open to Enrollment